, Indian Council of Medical Research (Advisory) (not included in the study count)
Revised advisory on the use of Hydroxych loroquine (HC Q) as prophylaxis for SARS-CoV-2 infection
Healthcare workers on HC
Q prophylaxis less likely to get COVID. Significant dose-response relationship. Extends recommended HC
Q prophylaxis to asymptomatic household contacts of cases and frontline workers. Degree of benefit not quantified.
Currently no formal study is available so this is not included in the study count.
Please send us corrections, updates, or comments: